“┎여직원 같이┚∋ yeotop5.com ∈ 송내동오피✄송내동키스방Ⅱ송내동오피✂송내동출장☨송내동안마ぜ송내동마사지❜송내동스파”的搜索结果，显示 181-190 项，共有 15052 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This is a randomized Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to: Establish a prospective database of all patients with peritoneal surface malignancies seen by Dr. Travis Grotz ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... 2 dose (RP2D) 1.1.2 To evaluate the safety and tolerability of this combination in a dose expansion cohort in patients with uterine serous carcinoma. A ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... 2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously ...